ClearPoint Neuro Q2 revenue record $5.2M (+52% YoY); reaffirms 2022 guidance

ClearPoint Neuro, Inc.

2022-Q2 EPS reported -$0.35 revenue$10,231,000

Quarterly revenue $5.2M (record), up 52% YoY; biologics/drug delivery revenue $2.4M +73%.
Partner PTC Therapeutics received EU marketing authorization for Upstaza; uses ClearPoint SmartFlow Neuro Cannula.
Reaffirmed FY2022 revenue guidance of $21-22M.
Cash and short-term investments $45.1M at June 30, 2022.
Added >45 partners; installed 8 systems YTD (4 in Q2).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.